1 min read
Add as a preferred source on Google

Jaguar Health Targets Mid-2027 MVID Filing After More Than $10 Million in Debt Reduction

Participants in the pivotal pediatric MVID trial have entered extension dosing. Jaguar also plans to seek breakthrough therapy designation in 2027.

An unmarked medicine container sits beside a measured dosing cup / TokenPost.ai (mono)
An unmarked medicine container sits beside a measured dosing cup / TokenPost.ai (mono)

Jaguar Health is targeting a mid-2027 new drug application submission for crofelemer to treat pediatric MVID after completing pivotal-trial enrollment, with participants now in extension dosing.

Jaguar plans to seek breakthrough therapy designation in 2027. The designation could potentially enable a four-month Food and Drug Administration review.

The company reduced its outstanding debt by more than $10 million in Q3 2026. The update adds clinical and debt milestones to Jaguar’s quarterly results, which included $2.343 million in revenue and a $9.23 net loss per share.

Jaguar’s prescription product net revenue was about $500,000 in Q3 2026, compared with about $1.2 million in Q2 2026. U.S. revenue from Mytesi and Canalevia-CA1 has been directed to Future Pak since Jan. 12, 2026. Jaguar supplies the products under cost-plus terms.

The company’s next stated milestone is its targeted mid-2027 NDA submission.

John Kim

John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.

Loading…